Home › Companies › Myriad Genetics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Myriad Genetics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 7 items on Myriad Genetics, Inc.’s Form 8-K, filed June 4, 2026: 3 approved · 4 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Myriad Genetics, Inc. in the interactive database Compare manager voting policies
These tallies are Myriad Genetics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Paul M. Bisaro | 61,842,900 | 637,156 | 23,264 | -- | 15,255,311 | 99% | Passed (calculated) | — |
| Elect Director: Rashmi Kumar | 60,399,633 | 2,071,375 | 32,312 | -- | 15,255,311 | 97% | Passed (calculated) | — |
| Elect Director: Lee N. Newcomer, M.D | 61,576,936 | 894,837 | 31,547 | -- | 15,255,311 | 99% | Passed (calculated) | — |
| 2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 | 76,302,595 | 1,391,172 | 64,864 | -- | -- | 98% | Approved | — |
| 3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement | 59,356,710 | 3,098,966 | 47,644 | -- | 15,255,311 | 95% | Approved | — |
| 4. Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan | 61,812,338 | 650,741 | 40,241 | -- | 15,255,311 | 99% | Approved | — |
| 5. Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan | 59,389,193 | 3,066,087 | 48,040 | -- | 15,255,311 | 95% | Passed (calculated) | — |
Source: Myriad Genetics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
227 asset managers disclosed a vote on at least one Myriad Genetics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Lee N. Newcomer, M.D.
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Lee N. Newcomer, M.D”): 61,576,936 for, 894,837 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 25,734,464 for, 79,551 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,809 | 8,364 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | Mixed |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Paul M. Bisaro
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Paul M. Bisaro”): 61,842,900 for, 637,156 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 25,734,465 for, 79,550 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,810 | 8,363 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | Mixed |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III Directors to serve until the 2029 Annual Meeting of Stockholders: Rashmi Kumar
Myriad Genetics, Inc.’s own tally for this item (“Elect Director: Rashmi Kumar”): 60,399,633 for, 2,071,375 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 25,563,365 for, 250,650 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,808 | 8,365 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,758 | 3,124 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 134,262 | 67,580 | 0 | 0 | Mixed |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 163,411 | 0 | 0 | Against |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: TO APPROVE THE PROPOSED AMENDMENT TO THE AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN.
Myriad Genetics, Inc.’s own tally for this item (“4. Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan”): 61,812,338 for, 650,741 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders voted to approve the proposed amendment to the Purchase Plan to increase the aggregate number of shares of common stock available for issuance under the Purchase Plan by an additional 4,000,000 shares.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 25,817,122 for, 2 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,674,170 | 2 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,402,882 | 0 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
95% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE THE PROPOSED 2026 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN.
Myriad Genetics, Inc.’s own tally for this item (“5. Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan”): 59,389,193 for, 3,066,087 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 24,031,486 for, 1,768,615 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,665,802 | 8,371 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,399,663 | 3,219 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 1,600,223 | 0 | 0 | Against |
| Aberdeen | 1,110,404 | 0 | 0 | 0 | For |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 0 | 85,615 | 0 | 0 | Against |
Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 92.1% for (June 5, 2025 meeting) ▲ 3.0 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
Myriad Genetics, Inc.’s own tally for this item (“3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 59,356,710 for, 3,098,966 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Myriad Genetics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (2 managers, 107 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,674,162 | 10 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,402,882 | 0 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 1,110,404 | 0 | 0 | Against |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 260,469 | 0 | 0 | Against |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 0 | 115,201 | 0 | 0 | Against |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Fund voting reports, all 65 managers: 24,320,242 for, 1,493,771 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GLENVIEW CAPITAL MANAGEMENT, LLC | 5,411,978 | 0 | 0 | 0 | For |
| State Street | 4,298,701 | 3,130 | 0 | 0 | For |
| DE Shaw | 4,296,492 | 0 | 0 | 0 | For |
| BlackRock | 4,190,341 | 817 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,322,984 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,826,477 | 0 | 0 | 0 | For |
| Charles Schwab | 1,802,669 | 0 | 0 | 0 | For |
| Federated Hermes | 1,778,967 | 0 | 0 | 0 | For |
| Invesco | 1,614,829 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,309,148 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,251,852 | 0 | 0 | 0 | For |
| AQR | 1,154,115 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 1,110,404 | 0 | 0 | Against |
| Fisher Asset Management, LLC | 915,070 | 0 | 0 | 0 | For |
| Vanguard | 884,820 | 0 | 0 | 0 | For |
| Two Sigma | 850,326 | 0 | 0 | 0 | For |
| Nuveen | 820,360 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 813,014 | 0 | 0 | 0 | For |
| Northern Trust | 789,200 | 0 | 0 | 0 | For |
| Fidelity | 587,165 | 0 | 0 | 0 | For |
| Goldman Sachs | 501,151 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 448,201 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 438,338 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 392,945 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 356,665 | 0 | 0 | 0 | For |
Institutional-manager reports, all 183 managers: 43,368,828 for, 2,169,081 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 95.6% for (June 5, 2025 meeting) ▲ 2.6 pts
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Myriad Genetics, Inc.’s own tally for this item (“2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026”): 76,302,595 for, 1,391,172 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was approved by stockholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 24,699,410 for, 1,114,604 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,670,068 | 4,105 | 0 | 0 | For |
| BlackRock | 4,269,304 | 0 | 0 | 0 | For |
| Fidelity | 2,725,101 | 0 | 0 | 0 | For |
| State Street | 2,402,787 | 95 | 0 | 0 | For |
| Charles Schwab | 1,802,397 | 0 | 0 | 0 | For |
| Federated Hermes | 1,600,223 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 1,110,404 | 0 | 0 | Against |
| TIAA | 792,458 | 0 | 0 | 0 | For |
| Goldman Sachs | 618,570 | 0 | 0 | 0 | For |
| Nationwide | 371,395 | 0 | 0 | 0 | For |
| Dimensional | 262,673 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 260,469 | 0 | 0 | 0 | For |
| Invesco | 235,299 | 0 | 0 | 0 | For |
| Equitable | 201,842 | 0 | 0 | 0 | For |
| AQR | 185,686 | 0 | 0 | 0 | For |
| Northern Trust | 163,411 | 0 | 0 | 0 | For |
| Voya | 154,901 | 0 | 0 | 0 | For |
| JPMorgan | 154,559 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 150,778 | 0 | 0 | 0 | For |
| GuideStone | 149,256 | 0 | 0 | 0 | For |
| Lincoln Financial | 133,151 | 0 | 0 | 0 | For |
| Northern Lights Fund Trust IV | 115,724 | 0 | 0 | 0 | For |
| MFS | 115,201 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 87,686 | 0 | 0 | 0 | For |
| American Century | 85,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 94,448,210 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.07% |
| 2 | BlackRock | 4.52% |
| 3 | Fidelity | 2.89% |
| 4 | State Street | 2.54% |
| 5 | Charles Schwab | 1.91% |
| 6 | Federated Hermes | 1.69% |
| 7 | Aberdeen | 1.18% |
| 8 | TIAA | 0.84% |
| 9 | Goldman Sachs | 0.65% |
| 10 | Nationwide | 0.39% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GLENVIEW CAPITAL MANAGEMENT, LLC | 5.73% |
| 2 | State Street | 4.55% |
| 3 | DE Shaw | 4.55% |
| 4 | BlackRock | 4.44% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.46% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 1.93% |
| 7 | Charles Schwab | 1.91% |
| 8 | Federated Hermes | 1.88% |
| 9 | Invesco | 1.71% |
| 10 | Vestal Point Capital, LP | 1.39% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock Portfolio Management LLC | 9,900,937 | 10.48% | Schedule 13G, filed September 4, 2026 |
| BlackRock | 8,889,644 | 9.41% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 8,225,371 | 8.71% | Form 13F, quarter ended March 31, 2026 |
| Millennium Management | 6,668,817 | 7.06% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 4,499,724 | 4.76% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,424,027 | 4.68% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 3,607,789 | 3.82% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 2,366,092 | 2.51% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 2,319,379 | 2.46% | Form 13F, quarter ended March 31, 2026 |
| Charles Schwab | 1,801,478 | 1.91% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 94,448,210 shares outstanding, as reported by Myriad Genetics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Myriad Genetics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 227 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 1,773 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — Myriad Genetics, Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Myriad Genetics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Myriad Genetics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Myriad Genetics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Myriad Genetics (MYGN) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/myriad-genetics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.